An interventional study of repetitive transcranial magnetic stimulation (rTMS) and sham rTMS in Laryngeal Dystonia and Focal Dystonia, sponsored by MGH Institute of Health Professions. Recruiting at 1 site in United States. Open to participants aged 21 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by MGH Institute of Health Professions · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Dysphonia with a site in United States — 20 open to participants now, 21 under way, 1 of them phase 3. Dysphonia · United States.
Among the 71 studies in Dysphonia with a site in United States, this one is the 32nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2021, is one of 31 with no phase, reaches primary completion later than 1 of the 20 other live ones, and was the 43rd registered.
132 studies on the registry are indexed under Dysphonia; 38 are open to participants now.
Browse Dysphonia studies →20 of the 71 studies in Dysphonia with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+
University of Minnesota · Sites in United States
Ages 18–75 · Healthy volunteers
Emory University · Sites in United States
Ages 16–65
University of California, San Diego · Sites in United States
Ages 18–89
Yale University · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Dysphonia studies recruiting now, 8 (32%) set no upper age limit and 9 (36%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.
This study: 21 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 4 · Phase 4 5
First in 1992; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 30 across 87 interventional studies indexed under Dysphonia.
Median enrollment 32 across the 53 interventional studies, 170 across the 18 observational. Of the 41 that completed or were terminated, 17 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 71 have an industry lead sponsor. The 10 most frequent:
MGH Institute of Health Professions is the lead sponsor of 19 studies on the registry; 12 are open to participants now.
MGH Institute of Health Professions has 1 study filed under Dysphonia — fewer than ten, so there is no comparison to draw.
12 of the studies in Dysphonia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07145086Phase 3Texas Christian UniversityTranslaryngeal Vibration for Hyperfunctional Voice Disorders | 2027-04-30 |
| NCT06830174Yale UniversitytDCS for Laryngeal Dystonia | 2026-12 |
| NCT03702322University of ArizonaImproving Voice Production for Adults With Age-related Dysphonia | 2026-12-30 |
| NCT05095740MGH Institute of Health ProfessionsEffects of Neuromodulation in Laryngeal Dystonia | 2026-12-31 |
| NCT07443891University of MinnesotaBrain Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 71 studies in Dysphonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Laryngeal dystonia (LD) causes excessive vocal fold abduction (opening) or adduction (closing) leading to decreased voice quality, job prospects, self-worth and quality of life. Individuals with LD often experience episodic breathy voice, decreased ability to sustain vocal fold vibration, frequent pitch breaks and in some cases, vocal tremor. While neuroimaging investigations have uncovered both cortical organization and regional connectivity differences in structures in parietal, primary somatosensory and premotor cortices of those with LD, there remains a lack of understanding regarding how the brains of those with LD function to produce phonation and how these might differ from those without LD. Intervention options for people with LD are limited to general voice therapy techniques and Botulinum Toxin (Botox) injections to the posterior cricoarytenoid (PCA) and/or TA (thyroarytenoid) often bilaterally, to alleviate muscle spasms in the vocal folds. However, the effects of injections are short-lived, uncomfortable, and variable. To address this gap, the aim of this study is to investigate the effectiveness of repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique, in assessing cortical excitability and inhibition of laryngeal musculature. Previous work conducted by the investigator has demonstrated decreased intracortical inhibition in those with adductor laryngeal dystonia (AdLD) compared to healthy controls. The investigators anticipate similar findings in individuals with with other forms of LD, where decreased cortical inhibition will likely be noted in the laryngeal motor cortex. Further, following low frequency (inhibitory) rTMS to the laryngeal motor brain area, it is anticipated that there will be a decrease in overactivation of the TA muscle. To test this hypothesis, a proof-of-concept, randomized study to down-regulate cortical motor signal to laryngeal muscles will be compared to those receiving an equal dose of sham rTMS. Previous research conducted by the investigator found that a single session of the proposed therapy produced positive phonatory changes in individuals with AdLD and justifies exploration in LD.
The cause of LD is largely unknown and there are no treatments that produce long-term benefits. The investigators' long-term goal is to elucidate the pathophysiology of laryngeal dystonia as a crucial step towards the development of sensitive testing and novel interventions to treat this devastating disease. Neuroimaging studies have suggested that LD is associated with abnormal patterns of activation and excessive plasticity in sensorimotor areas in the brain, however, an understanding of the cortical excitability in this disorder is lacking. This information is important because it provides a more comprehensive understanding of the pathophysiology of the disorder, opening potential investigation into novel tests or treatments. The investigators have begun to address this gap in knowledge by developing a novel transcranial magnetic stimulation (TMS) paradigm to assess intracortical excitability and inhibition of targeted laryngeal muscles. Although similar paradigms have been fruitful for explicating the neural mechanisms of dystonia in the limbs, to our knowledge TMS has not been used to assess pathophysiology in laryngeal dystonia, thus similarities and differences in brain state between the limb and laryngeal dystonias could not be assessed. The investigators' current NIDCD project (R01DC015216) with which this proposed project synergizes, uses TMS and functional neuroimaging in people with LD and focal hand dystonia to determine the brain excitability and connectivity, distinctive of, and common to the two disorders. This approach is based on the investigators' recently completed NIDCD grant (R21DC012344) which supported the development of a valid and reliable TMS method to determine the cortical representation and excitability of the thyroarytenoid, a muscle affected in LD. Utilizing this approach, the investigators have recently demonstrated that people with LD have reduced intracortical inhibition compared to healthy controls. These results provide a compelling basis for the clinical application of this finding to determine if an intervention that increases intracortical inhibition can produce clinical improvements.
Aim 1: Determine the phonatory effects of 5-days of daily rTMS vs sham in people with LD. The effects of rTMS on phonatory function will be measured using (a) auditory-perceptual assessment (b) acoustic analysis including smoothed cepstral peak prominence (CPPS) of running speech and sustained vowel, and (c) patient self-ratings of vocal effort (response to voice demand). (H1) The investigators will observe large favorable intervention effect sizes in measures of phonatory function following rTMS compared to sham.
Aim 2: Determine the neurophysiologic changes associated with 5 days of rTMS vs sham in people with LD. The intervention effects on TMS-measured neurophysiology including intracortical excitatory and inhibitory measures from the laryngeal motor cortex will be assessed pre and post intervention. (H2) The investigators will observe significant decreases in cortical excitability [motor evoked potential (MEP)] and/or increases in inhibition [cortical silent period (cSP)] following rTMS compared to sham.
Aim 3: Explore characteristics associated with responders vs non-responders to rTMS in people with LD. This exploratory aim will stratify participants as responders or non-responders based on each person's acoustic (CPPS) changes. A multivariate regression will explore factors associated with positive response to intervention. (H3) Certain factors such as age, time since symptom onset, clinical severity, and/or baseline cortical excitability and inhibition will be associated with treatment responsiveness.
Procedures: Qualified participants will provide informed consent and receive on-site screening to determine eligibility. On Day 1, baseline (Pre) acoustic, perceptual and patient-reported assessments of voice production and TMS-measured neurophysiology will be performed. Participants will then receive the first rTMS intervention. On Day 2, 3 and 4, participants will receive rTMS (real or sham) intervention solely, with no testing. On Day 5, the same acoustic, perceptual, patient-reported and neurophysiologic assessments will be performed after rTMS intervention. At least 3 months after Post1, participants will cross-over to receive the other intervention (rTMS or Sham). The timing of the assessments in the cross-over phase of the experiment, Pre2 and Post2, will mirror the timing of Pre1 and Post1 in the first phase.
TMS Neurophysiology Assessment. Participants will have the vocalization area tested. Topical anesthesia will first be applied to the anterior neck skin followed by a superficial injection of 1% lidocaine with 1:100,000 epinephrine. The target muscles are bilateral TA muscles. A 30 mm, 27 gauge needle loaded with a pair of fine-wire hooked electrodes will be inserted into each TA muscle by an experienced otolaryngologist following standard procedures for laryngeal EMG. Using a percutaneous approach, the needle will be passed through the cricothyroid membrane at an angle off midline but medial to the ipsilateral inferior tubercle, to directly enter the TA muscle while avoiding the airway. During insertion, the electrodes are connected to an audio monitor to monitor muscle activity in real-time during placement. After the TA placement is confirmed, the needle is removed leaving the fine-wires in the TA muscles. The two pairs of fine-wire electrodes will be connected to the amplifier and acquired with the same setup that are reported in the investigators' previous study. electrode locations will be confirmed by increased EMG activity with sustained phonation and Valsalva maneuver. The TMS testing intensity threshold will be determined by finding the minimum intensity required to elicit a cortical silent period (cSP) during constant phonation of /i/ (to elicit contraction from the TA muscles) as a measure of cortical inhibition. The TMS 'hotspot' will be the corresponding location on the cortex when cSP is induced with the TMS testing intensity threshold. TMS hotspot location and 30 trials of fine-wire electrodes electromyogram (EMG) cSP response from TA muscle will be recorded. The cSP reflects GABAB receptor mediated inhibitory processes within cortical motor areas. Ten trials motor evoked potential (MEP) will also be evoked with the participants as rest as a measure of cortical excitability. EMG area under the curve will be calculated for a time-equivalent period of pre-stimulus activity. A frameless stereotactic neuro-navigation system will be used to enhance the reliability and recording of stimulus locations. To ensure safety, an investigator will screen each participant to determine appropriateness for TMS and that all safety parameters are met. Processing will occur according to previously published methods. The investigator performing the excitability assessment will be blind to group designation.
rTMS. Inhibitory (1 Hz) rTMS (1200 pulses, biphasic waveform) will be delivered to the same left hemisphere laryngeal motor cortical 'hotspot' established with the TMS testing on Day 1. The left laryngeal cortex was selected due to the bilateral nature of control of the laryngeal muscles, and findings of no difference between left and right sided cSP. Neuronavigation (Brainsight®, Rogue Research Inc. Quebec, Canada) will be used to enhance rigor by tracking stimulation location in the cortex and coil position as the stimulation target. Subject will receive approximately 20 minutes of FDA-approved rTMS treatment at 0.9 x resting motor threshold at 1 Hz with a 70-mm figure-eight TMS coil connected to 5Magstim rapid magnetic stimulator. This treatment is within the range for total pulses performed in previous studies in subjects with other dystonias in a single day. The same target will be used for the rTMS intervention over the 5 days and for the post-intervention assessments. Sham rTMS stimulation will be delivered with a sham coil that produces similar sound and sensory stimulation to the scalp but does not deliver a stimulating pulse. Sham stimulation will help deter mine whether the changes following rTMS are due to placebo effect.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 consecutive days of rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
Device: repetitive transcranial magnetic stimulation (rTMS)
5 consecutive days of sham rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
Device: sham rTMS
Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
Also known as: transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
Also known as: sham repetitive transcranial magnetic stimulation
Change in Objective Assessment of Phonatory Function
Participants will produce sustained /ah/ vowels, read the rainbow passage and engage in freeform conversation. This speech will be recorded and measures of cepstral peak prominence smoothed (CPPS; range: 0-100, where higher indicates stronger voice signal and correlates highly with better voice quality).
Time frame: Day 1 (baseline), day 5 (post intervention), and Day 12 (follow up) timepoints for both arms of the study.
Change in Cortical Excitability (intrahemispheric inhibition)
Intrahemispheric inhibition will be measured with the cortical silent period (cSP) measured in ms
Time frame: Day 1 (baseline), Day 5 (post intervention)
Subjective Assessment of Phonatory Function
Three speech language pathologists who specialize in voice disorders and are blinded to treatment day or group, will listen to the recorded audio sentences and sustained vowels and perform an independent overall perceptual evaluation of each participant's voice for each assessment session using the rating scales from the American Speech-Language-Hearing Association recommended Consensus Auditory Perceptual Evaluation of Voice (CAPE-V). The primary measure will be the rating for Overall Severity of dysphonia, and secondary measures will include ratings for strain, roughness, breathiness, pitch and loudness. Scores closer to 0 indicate less severity and closer to 100 indicate more severely disordered. Each judge will listen to recordings of 20% of the assessments (randomly selected) twice for purposes of estimating intra-judge reliability. Ratings from the three judges will be averaged to produce one score for each perceptual parameter.
Time frame: Day 1 (baseline), Day 5 (post intervention), and Day 12 (follow up) timepoints for both arms of the study.
Self Ratings of Voice Effort
Self ratings of voice effort on a visual analog scale (VAS) after reading the sentences in Outcome 1. "Speaking required how much effort?" 0=minimal effort, 10= maximal effort
Time frame: Day 1 (baseline), Day 5 (post intervention), and Day 12 (follow up) timepoints for both arms of the study.
Secondary Objective assessment of phonatory function
In addition to the CPPS (primary measure above), the voice samples will be analyzed with the following: number of phonatory breaks (range: 0-x; were few breaks indicates a better voice quality), frequency shifts (range: 0-x Hz; where a smaller shift (closer to 0) is generally indicative of better voice quality) and the number of aperiodic segments (range: 0-x; where fewer aperiodic voice segments is generally indicative of better voice quality) will be obtained from each recording. These will be analyzed and compared over time.
Time frame: Day 1 (baseline), Day 5 (post intervention), and Day 12 (follow up) timepoints for both arms of the study.
Forced choice paired assessment of phonatory function
If the primary or secondary assessments of objective or perceptual ratings of change fail to capture change in participants' voice between baseline and post intervention, a forced choice question will be posed to blinded raters to ask which paired voice sample represents the less severe sample and then perform a VAS ranking of how severe the voice sample sounds (0=minimal impairment, 10=severe impairment)
Time frame: Day 1 (baseline), Day 5 (post intervention), and Day 12 (follow up) timepoints for both arms of the study.
Plan to share: Yes — The investigators will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate technology; and (3) a commitment to destroying or returning the data after analyses are completed. Sharing and modification rights will be determined for individual users by the PI of this study.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available no later than upon the acceptance of publication of the final dataset.
Access criteria: Listed as personnel on Massachusetts General Hospital individualized health plan institutional review board for this study and as determined by the principal investigator.
Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.
Of 44 non-industry interventional studies with no phase under Dysphonia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 66 months is above that.
Counting every sponsor, half of 44 studies reached it within 26 months; a quarter within 11 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MGH Institute of Health Professions